EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study

Takanori Azuma, Kenta Misaki, Makio Kusaoi, Yoko Suzuki, Shinji Higa, Yoshitaka Kumon, Tamami Yoshitama, Taio Naniwa, Shinsuke Yamada, Tadashi Okano, Kimihiko Takeuchi, Kei Ikeda und 15 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Takanori Azuma und 26 weiteren Autor:innen. Beteiligte Einrichtung: Azuma Rheumatology Clinic, Saitama, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-naïve patients with rheumatoid arthritis.

Methods

Enrolled patients (n = 325) were divided into two groups according to whether abatacept was prescribed without (MTX−) or with (MTX+) concomitant MTX. We compared the changes in Simplified Disease Activity Index (SDAI), Disease Activity Score-28 with C-reactive protein (DAS28-CRP), and Japanese Health Assessment Questionnaire (J-HAQ) through to 52 weeks of treatment, the abatacept retention rate, and safety.

Results

At Week 52, the mean SDAI (8.9 vs. 8.8), DAS28-CRP (2.6 vs. 2.6), and J-HAQ (0.92 vs. 0.91) scores were comparable in the MTX− (n = 129) and MTX+ (n = 150) groups. Multivariable logistic regression revealed no significant association between MTX use and SDAI (low disease activity) or J-HAQ (minimum clinically important difference). The abatacept retention rates, estimated using the Kaplan–Meier method, were 73.2% and 66.7% in the MTX− and MTX+ groups, respectively. Adverse events occurred in 47.5% (of 139) and 52.2% (of 159) of patients in the MTX− and MTX+ groups, respectively.

Conclusion

The effectiveness and safety of abatacept appeared comparable with or without concomitant MTX in this real-world clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsHumansMethotrexateAbataceptTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

Abataceptdisease-modifying antirheumatic drugmethotrexatereal-worldrheumatoid arthritis

Substanzen

MethotrexateAbataceptAntirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Azuma Rheumatology Clinic, Saitama, Japan.
  • Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan.
  • Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
  • Izumi Himawari Clinic, Miyagi, Japan.
  • Division of Rheumatology, Daini Osaka Police Hospital, Osaka, Japan.
  • Department of Rheumatology, Chikamori Hospital, Kochi, Japan.

Förderung

  • Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., Ltd.

Zitieren

APA

Azuma, T., Misaki, K., Kusaoi, M., Suzuki, Y., Higa, S., Kumon, Y., Yoshitama, T., Naniwa, T., Yamada, S., Okano, T., Takeuchi, K., Ikeda, K., Higami, K., Inoo, M., Sawada, T., Kang, C., Hayashi, M., Nagaya, Y., Hagiwara, T., …, & Harigai, M. (2023). Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study. Modern Rheumatology. https://doi.org/10.1093/mr/roac032

Vancouver

Azuma T, Misaki K, Kusaoi M, Suzuki Y, Higa S, Kumon Y, et al. Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study. Modern Rheumatology. 2023. doi:10.1093/mr/roac032

BibTeX
@article{Azuma2023,
  author = {Azuma, Takanori and Misaki, Kenta and Kusaoi, Makio and Suzuki, Yoko and Higa, Shinji and Kumon, Yoshitaka and Yoshitama, Tamami and Naniwa, Taio and Yamada, Shinsuke and Okano, Tadashi and Takeuchi, Kimihiko and Ikeda, Kei and Higami, Kenshi and Inoo, Masayuki and Sawada, Tetsuji and Kang, Chonte and Hayashi, Masatoshi and Nagaya, Yuko and Hagiwara, Takafumi and Shono, Eisuke and Himeno, Shinkichi and Tanaka, Eiichi and Inoue, Eisuke and Yoshizawa, Yuri and Kadode, Michiaki and Yamanaka, Hisashi and Harigai, Masayoshi},
  title = {Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac032}
}
Kostenlos starten →